|Bid||95.00 x 382500|
|Ask||106.00 x 252100|
|Day's range||99.85 - 103.80|
|52-week range||88.90 - 166.97|
|PE ratio (TTM)||-14.77|
|Earnings date||21 Nov 2017 - 27 Nov 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||163.27|
Oct (Shenzhen: 000069.SZ - news) 4 (Reuters) - British drugmaker Vectura said its asthma inhaler Flutiform had made favourable regulatory progress in Europe, and it can now apply for approvals through its partner. Vectura said its partner Mundipharma confirmed a "successful outcome" for the inhaler, when first assessed by the UK medicines and healthcare products regulatory agency -- which covers 18 countries across Europe. "This positive DCP outcome is an important step in the regulatory process and Mundipharma can now begin to apply for national approvals and reimbursement in the European countries covered by this procedure", Chief Executive Officer James Ward-Lilley said in a statement on Wednesday.
British drugmaker Vectura reported a doubling in first-half losses and warned full-year revenues would be hit by customers running down stocks of asthma inhaler Flutiform, sending its shares as much as 14 percent lower on Wednesday. The company, which bought rival SkyePharma (LSE: 4547152.L - news) for 441 million pounds ($575 million) in June 2016, said full-year revenues from product supplies and device sales were likely to be flat on a comparable basis with the previous year. "Although Vectura has undertaken to lower its R&D expense to compensate such that the net effect is 'broadly neutral at earnings,' we think the market may be disappointed by the implied negative change to 2017 earnings mix," they wrote in a research note, keeping a "hold" rating on the stock.
Sept 6 - Vectura said revenue rose 6 percent in the first half of the year, driven by rising sales of its recently launched inhaled products and the continued weakness of sterling against a basket of its ...
GlaxoSmithKline (Other OTC: GLAXF - news) is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent form of the medicine was turned down by U.S. regulators. Hikma Pharmaceuticals (Frankfurt: A0HG69 - news) said on Thursday the Food and Drug Administration (FDA) had decided not to approve its version of the inhaled treatment for asthma and chronic lung disease at this time, due to "major" issues with the application. Hikma and its partner Vectura are in a race with Mylan to launch the first U.S. generic copy of Advair that can be substituted for the original product in pharmacies.
** Drugmaker Hikma down 8 pct, bottom of Stoxx 600 , with its partner Vectura -9% ** Hikma says US regulators have decided not to approve its generic copy of GlaxoSmithKline's blockbuster lung drug Advair ...
** Shares in Hikma Pharmaceuticals and its partner Vectura down 1.6% and 2.3% on speculation U.S. regulators won't grant immediate approval for generic version of GlaxoSmithKline's blockbuster inhaled ...
GlaxoSmithKline's new CEO Emma Walmsley, who takes over on April 1, has won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan (Hamburg: 27249935.HM - news) 's copy of the blockbuster lung inhaler. It is unclear how long Mylan will have to wait to get its version of the asthma and chronic lung disease medicine on the market, after receiving a so-called complete response letter (CRL) from the U.S. Food and Drug Administration (FDA).
Drugmaker Hikma Pharmaceuticals Plc posted higher than expected full-year profit thanks to higher margins and said it expects profitability in its growing generics drugs business to improve significantly this year. Shares (Berlin: DI6.BE - news) in Hikma, which makes and markets branded and non-branded generic and injectable drugs and is listed on the FTSE 100 in London, rose as much as 9 percent to 2317 pence and was the top gainer on the index. Hikma, which bought Boehringer Ingelheim's U.S. generic drugs business last year maintained its expectation of $800 million in revenue from the generics business in 2017, in line with a reduced forecast it made in November.
GlaxoSmithKline (Other OTC: GLAXF - news) quarterly sales and profits beat expectations, buoyed by a weak pound, but the drugmaker warned earnings stripping out currencies could slip in 2017 if generic copies of its lung drug Advair arrive in the United States. Outgoing Chief Executive Andrew Witty, presenting his final set of results, said the 2017 profit outlook was "very consistent" with market consensus and showed GSK was well placed to absorb the potential loss of Advair. GSK is buttressed by its large consumer health and vaccines units, while the core pharmaceuticals business is seeing increased demand for new drugs.